Clinical trial NCT03917667: Sarcopenia in Acute Care Patients: Protocol for Sarcopenia 9+
Official title: Sarcopenia in Acute Care Patients: Protocol for Sarcopenia 9+
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Sarcopenia
Keywords: Sarcopenia
Lead sponsor: Brugmann University Hospital
Sponsor class: OTHER
First posted: 2019-04-17
Enrollment: 100
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients aged 70 years and older who are admitted to the acute care geriatric units of the CHU Brugmann Hospital. This may include acute medical conditions or chronic disease decompensation; patients are eligible for referral to acute geriatric units due to medical diseases, such as urinary tract infections, respiratory tract infections, pneumonia, coronary heart diseases, atrial fibrillation, congestive heart failure, stroke, delirium, electrolyte disturbances, kidney disease, cancer, etc...

Brief summary: Sarcopenia is a disease characterized by progressive and generalized loss of skeletal muscle mass and strength, and is related to worse clinical outcomes, physical impairment, and mortality in all healthcare settings. This nutrition-related syndrome is a reversible condition, and can be effectively counteracted by exercise and nutritional support.

The prevalence of sarcopenia varies widely depending on the criteria, methods, and cut-off points used for its assessment. Although the European Working Group on Sarcopenia in Older People (EWGSOP) recommended assessing sarcopenia in geriatric patients in all care settings, few studies addressing hospitalized older patients have been carried out, mainly due to the characteristics of acute healthcare settings and their in-patients and because the criteria used are difficult to carry out there. Therefore, this condition remains under-recognized in the setting where this disease is likely to be more present.

Sarcopenia is expected to be a major healthcare problem in the upcoming years in Europe so, in response to this claim for Public Health Action, the European Union Geriatric Medicine Society founded the Special Interest Group (SIG) on sarcopenia that has taken the lead of bridging the gaps between clinical and research in sarcopenia field, in line with the Conference on Frailty and Sarcopenia Research Task Force, and the World Health Organization's strategies to promote Optimal Aging. This goal of SIG on sarcopenia by EuGMS is being carried out by promotion of collaboration among International scientific societies and institutions; they have recently launched the Revised European consensus on definition and diagnosis (EWGSOP2), the SARCUS project on ultrasound for sarcopenia assessment in European countries, and the first International Registry of patients with sarcopenia.

This study aims to provide an overview of sarcopenia assessment older patients hospitalized in acute-care geriatric units.

This is a longitudinal, prospective, observational study in consecutive hospitalized patients in the CHU Brugmann Hospital.

This study has 5 objectives :

1. To determine prevalence of sarcopenia among hospitalized patients in CHU Brugmann.
2. To determine incidence of sarcopenia during the hospital stay.
3. To identify risk factors for the development of sarcopenia at the time of admission and during hospitalization.
4. To assess sarcopenia as a risk factor for clinical adverse outcomes during hospitalization (hospital-acquired infections, falls, delirium, longer length-of-stay, disability, and mortality).
5. To assess sarcopenia as a risk factor for clinical adverse outcomes post-discharge (institutionalization, hospitalizations, falls, disability, and mortality) at 3- and 12-month follow-up.


Eligibility criteria: Inclusion Criteria:

- Patients aged 70 years and older who are admitted to the acute care geriatric units of the CHU Brugmann Hospital.

Exclusion Criteria:

* Hip or lower limbs fractures, amputations,
* Terminally ill patients admitted for palliative care,
* Neurological patients with hemiplegia or stroke limiting the walking evaluation

Primary outcomes:
measure: Prevalence of sarcopenia at hospital admission
timeFrame: 72 hours
measure: Incidence of sarcopenia between admission and discharge
timeFrame: Up to 20 days
measure: Occurence of risk factors
timeFrame: Up to 20 days
measure: Occurence of adverse events
timeFrame: Up to 20 days
measure: Occurence of adverse events
timeFrame: 3 months after hospital discharge
measure: Occurence of adverse events
timeFrame: 1 year after hospital discharge
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: CHU Brugmann
city: Gent
country: Belgium
facility: UZ Gent
Study officials:
affiliation: CHU Brugmann
name: Murielle Surquin, MD
role: PRINCIPAL_INVESTIGATOR
References: